Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

Alcidion Group’s A$0.14 price target is being held steady, with the unchanged A$0.1425 fair value reinforcing that analysts are not shifting their core valuation anchor right now. That stability lines up with broader medtech coverage, where peers have seen both upgrades and cuts as models are refreshed after Q4 reporting and sector updates. As you read on, you will see how this static price target fits into the evolving analyst narrative and what to watch as new information comes through.

Stay updated as the Fair Value for Alcidion Group shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Alcidion Group.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

Across medtech, several firms like Wells Fargo, Barclays and BTIG have been willing to lift price targets or upgrade names when they see product traction and steady execution after Q4 results. This helps explain why Alcidion’s unchanged A$0.14 target is not out of step with a sector where valuation anchors tend to move only when new evidence is strong. Wells Fargo’s upgrade of Alcon to Overweight with a higher US$97 price target, along with Barclays and BTIG nudging their targets higher, shows that when analysts gain confidence in product pipelines and cash generation, they are comfortable assigning higher fair values. This framework can also influence how they think about smaller health tech names like Alcidion over time.

🐻 Bearish Takeaways

Stifel’s downgrade of Alcon to Hold, and Berenberg’s reduction in its price target, highlight that medtech valuations can be sensitive when survey work or market assumptions look less supportive. This is a useful reminder that Alcidion’s A$0.1425 fair value could be revisited if sector data or company level execution were to disappoint. William Blair’s neutral stance on Alcon and BTIG’s cautious tone on Staar Surgical underline that some analysts prefer to wait for greater clarity before getting more constructive. That same caution can keep a lid on how aggressively the market is willing to price Alcidion’s growth prospects today.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!ASX:ALC 1-Year Stock Price Chart

We've flagged 1 risk for Alcidion Group. See which could impact your investment.

What's in the News

Alcidion Group is assessing potential M&A opportunities, with management describing the process as selective and aligned to the three growth pillars outlined on the Half Year Results Webinar for the six months ending 31 December 2025. The company reaffirmed its fiscal 2026 guidance, expecting revenue to exceed A$50.0 million. At 31 December 2025, Alcidion reported contracted sold and renewal revenue for fiscal 2026 of A$43.1 million, which the company described as 40% above the prior corresponding period and 6% above fiscal 2025 full year revenue.

Story Continues

How This Changes the Fair Value For Alcidion Group

Fair value is held at A$0.1425, with no change to the core valuation anchor used. Revenue growth is kept effectively steady at 4.33%, with no adjustment to top line assumptions. Net profit margin remains around 6.19%, with only a very small numerical adjustment. Future P/E stays broadly consistent at about 70.7x, with no effective change to the earnings multiple. The discount rate is adjusted marginally from 8.11% to 8.12%, reflecting a very small change in the applied hurdle.

Never Miss an Update: Follow The Narrative

Narratives link a company’s business story to a financial forecast and fair value, so you can see how headlines, contracts and guidance connect to the numbers. They update automatically when new data or research is added, which helps keep your thesis current.

Head over to the Simply Wall St Community and follow the Narrative on Alcidion Group to stay up to date on:

How Alcidion’s Miya Precision platform and modular contracts support recurring revenue through digital healthcare transformation in markets like the UK, Canada, Saudi Arabia and the UAE. Why operational leverage, leadership hires and a land and expand approach with existing clients are important for recurring earnings and margin resilience. Key risks such as reliance on a few large UK contracts, potential delays in contract renewals and funding decisions, and cost pressures from international expansion and regulatory requirements.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ALC.AX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments